Los Angeles, April 12 (CNA) Two new drugs, developed by a Taiwanese company for the treatment of schizophrenia and designated by the U.S. Food and Drug Administration (FDA) as breakthrough therapy, will undergo late stage trials this year, according to the company’s founder and CEO.
The two drugs, named SND-12 and SND-13, were developed by SyneuRx International (Taiwan) Corp, which focuses on the treatment of unmet medical needs in central nervous system disorders in Taiwan.
“represents the third generation antipsychotic that not only addresses the positive symptoms like exaggerations and distortions of normal perception and thinking but, more importantly, the negative symptoms such as inexpressive faces, blank looks, monotone and monosyllabic speech, seemingly lack of interest, and inability to feel pleasure or act spontaneously, that the available antipsychotics cannot improve.”
snd121 and snd131 according to the Syneurx website are trials of NaBen or sodium benzoate added on to clozapine. These are trials for sodium benzoate for schizophrenia, one of the major main frontiers in pre 2020 schizophrenia research pipeline.
